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PCardiac Resynchronization Therapy
Cardiac Resynchronization
in Patients With Atrial Fibrillation
A Meta-Analysis of Prospective Cohort Studies
Gaurav A. Upadhyay, MD,* Niteesh K. Choudhry, MD, PHD,† Angelo Auricchio, MD, PHD,‡
Jeremy Ruskin, MD,* Jagmeet P. Singh, MD, PHD*
Boston, Massachusetts; and Lugano, Switzerland
Objectives This study is a meta-analysis of prospective cohort studies comparing the impact of cardiac resynchronization
therapy (CRT) for patients in atrial fibrillation (AF) and sinus rhythm (SR).
Background Although close to one-third of advanced heart failure patients exhibit AF, the impact of CRT in this group re-
mains unclear.
Methods Prospective cohort studies comparing patients in normal SR and chronic AF treated with CRT were included. All
studies reported death, New York Heart Association functional class, ejection fraction, 6-min walk test, and the
Minnesota score or its equivalent as outcomes. Data sources included Ovid MEDLINE In-Process & Other Non-
Indexed Citations, the Cochrane Central Register of Controlled Trials, the Database of Abstracts of Reviews of
Effects, and the American College of Physicians Journal Club.
Results Of 2,487 reports identified, 5 studies following a total of 1,164 patients were included. Both AF and SR patients
benefited significantly from CRT. Mortality was not significantly different at 1 year (relative risk ratio: 1.57, 95%
confidence interval [CI]: 0.87 to 2.81). The New York Heart Association functional class improved similarly for
both groups (0.90 for SR patients, 0.84 for AF patients). SR patients showed greater relative improvement in
the 6-min walk test (11.6 m greater, 95% CI: 10.4 to 12.8 m) and the Minnesota score (3.9 points less, 95% CI:
3.4 to 4.5 points) than AF patients. AF patients, however, achieved a small but statistically significant greater
change in ejection fraction (0.39% greater change in ejection fraction, 95% CI: 0.22% to 0.55%).
Conclusions Patients in AF show significant improvement after CRT, with similar or improved ejection fraction as SR patients,
but smaller benefits in regard to functional outcomes. (J Am Coll Cardiol 2008;52:1239–46) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.06.043o
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Qeart failure continues to be the most frequent cause of
ospitalization among the elderly, with annual health care
osts totaling $33.2 billion in the U.S. alone (1,2). Although
dvances in diagnostic and pharmacotherapeutic strategies
ave led to improved survival in the past 2 decades, the
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ccepted June 7, 2008.bserved benefits have been modest and variable among
iverse groups of heart failure patients (3–5).
See page 1247
In recent years, the armamentarium of treatment options for
eart failure patients has expanded to include new device-based
nterventions: specifically, atrial-synchronized biventricular
ardiac pacemakers or cardiac resynchronization therapy
CRT). Targeted toward patients with left ventricular dysfunc-
ion and mechanical dyssynchrony, CRT offers additive mor-
ality and morbidity benefits beyond medication (6,7). Large-
cale randomized clinical trials evaluating CRT have validated
ts use for patients in sinus rhythm on stable medical therapy,
ymptomatically severe New York Heart Association (NYHA)
eart failure, significant systolic dysfunction, and prolonged
RS duration (8–13).
Importantly, although close to one-third of patients withdvanced heart failure show atrial fibrillation (AF), there is
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impact of CRT in this subgroup
(14). Previous systematic reviews
of randomized clinical trials have
evaluated the impact of CRT on
morbidity and mortality for pa-
tients in sinus rhythm, largely
excluding patients with AF
(6,7,15,16). Recently reported
data from smaller prospective co-
hort studies now make it possible
to begin to assess the clinical
benefit of CRT for patients with
AF. Accordingly, we conducted
a meta-analysis to determine the
differential impact of CRT for
patients in AF and sinus rhythm.
Methods
earch strategy. We performed an electronic literature
earch of MEDLINE (1950 to May 2007), MEDLINE
n-Process & Other Non-Indexed Citations, Cumulative
ndex to Nursing & Allied Health Literature, the Cochrane
atabase of Systematic Reviews (Second Quarter, 2007),
he American College of Physicians Journal Club (1991 to
ay/June 2007), Database of Abstracts of Reviews of
ffects, and the Cochrane Central Register of Controlled
rials using the following search terms: heart, cardiac,
iventricular pacing, biventricular pacemaker, cardiac resyn-
hronization therapy, resynchronization therapy, or cardiac
esynchronization. We conducted additional searches based
n 9 trial acronyms that are frequently cited in narrative
eviews of cardiac resynchronization. We also hand searched
he bibliographies of all review articles published in the past 5
ears regarding the role of CRT or cardiac resynchronization
nd patients with AF.
Studies reporting the impact of CRT on mortality,
chocardiographic data (e.g., ejection fraction), and func-
ional outcomes (e.g., NYHA functional class, 6-min walk
est, and quality of life [QOL] as measured by the Minne-
ota Living with Heart Failure (MLWHF) questionnaire)
n patients with sinus rhythm and chronic AF were selected.
e included both published data from subgroups in ran-
omized trials and published prospective cohort studies.
eports in which the majority of AF patients developed AF
fter enrollment or had primarily intermittent or paroxysmal
F were excluded, as were studies with a total number of
25 participants and those that did not present original
esearch data (e.g., letters, commentaries, reviews, or study
esign articles).
ata extraction. Two investigators (G.A.U. and J.P.S.)
ndependently extracted data on patient and study charac-
eristics, outcomes, and study quality for each trial using a
tandardized protocol and reporting form. Disagreements
Abbreviations
and Acronyms
6MWD  6-min walking
distance
AF  atrial fibrillation
AVJ  atrioventricular
junction
CI  confidence interval
CRT  cardiac
resynchronization therapy
LVEF  left ventricular
ejection fraction
MLWHF  Minnesota
Living With Heart Failure
NYHA  New York Heart
Association
QOL  quality of lifeere resolved by consensus. vata analysis. We calculated relative risks for dichotomous
utcomes (e.g., mortality) using the DerSimonian and Laird
andom effects models. For continuous outcomes, weighted
ean differences were calculated using Mantel-Haenszel
xed-effects models. Only outcomes in which 3 or more
tudies reported on results were combined in our weighted
ean difference calculations. Heterogeneity was quantified
sing the I2 statistic (17). Statistical analyses were con-
ucted using Review Manager 4.3 (The Cochrane Collab-
ration, Copenhagen, Denmark), and 95% confidence in-
ervals (CIs) were reported for all results. For trials that
eported results at multiple time points, we used 6- or
2-month follow-up data to ensure comparability between
tudies. In the case of Linde et al. (18), results used were
hose documented for patients who had completed the
andomization crossover periods.
esults
earch results. The initial search yielded 2,487 results, of
hich 5 (4 prospective cohort studies [19–22] and a
ubgroup of 1 randomized clinical trial [18]) met our
nclusion criteria (Fig. 1). The studies included a total of
,164 patients, of whom 797 were in sinus rhythm and 367
ere in AF. Table 1 summarizes the baseline characteristics
or patients enrolled in each study. Taken together, the
eighted average age of patients was 66 years, with patients
n AF being 1.6 years older on average (p  0.005). Most
atients (78%, weighted average) were men. More AF
atients had NYHA functional class III to IV heart failure
han those in sinus rhythm (99.6% and 89.0%, respectively).
mong 841 patients in whom the cause of heart failure was
eported, 42% were identified as having ischemic cardiomy-
pathy (18,19,21).
The quality of the studies included is limited in that the
ajority are prospective cohort studies rather than random-
zed trials. The inclusion criteria for enrollment were similar
cross studies and were consistent with the generally ac-
epted criteria for the large-scale randomized trials validat-
ng CRT, however, including: electrocardiographic evidence
f conduction delay (QRS duration120 ms or QRS200
s for paced patients), severe symptomatic heart failure
NYHA functional class III to IV patients), and significant
ystolic dysfunction (left ventricular ejection fraction
LVEF] 35%). Exceptions included the enrollment of a
inority of NYHA functional class II heart failure patients
n 2 studies (21,22) and the use of a longer QRS interval
QRS 150 ms) for entry in 1 trial (18). All patients were
n a stable combination of medical therapy for heart failure
efore enrollment including beta-blockade, angiotensin in-
ibition, and use of diuretics.
evice implantation and use of atrioventricular junction
AVJ) ablation. The implantation site of the left ventricu-
ar lead in all studies was in a tributary of the coronary sinus,
sually in a lateral or posterolateral cardiac vein. The
enography-guided, transvenous approach was the preferred
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October 7, 2008:1239–46 Cardiac Resynchronization in AFodality of placement used, although an epicardial ap-
roach via limited thoracotomy was used in 1 study for a
andful of technically difficult cases (21). Two studies
mplanted combination CRT and defibrillation (i.e.,
RT-D) devices where necessary along with conventional
RT devices (20,21). Patients with preserved sinus rhythm
ere programmed to receive atrial-synchronous sequential
acing (DDD), and the majority of AF patients were paced
n a biventricular rate adaptive (VVIR) mode. Four of 33
F patients in the MUSTIC (MUltisite STimulation In
ardiomyopathy) trial (18), however, preferred right ven-
ricular VVIR pacing after the crossover period, and were
rogrammed accordingly.
The use of AVJ ablation was variable across AF patients,
etween 22% in Delnoy et al. (22) to 100% in Leclerq et al.
19), with an overall rate of 56% across patients in this
nalysis (Table 2). Gasparini et al. (21) prospectively deter-
ined that all AF patients who achieved 85% biventricu-
Figure 1 Search Flow Diagram For Reports Included in the Met
AF  atrial fibrillation.ar pacing would undergo AVJ ablation. In Delnoy et al. a22), AVJ ablation was performed in only 2 patients after
acemaker implantation. All other use of AVJ ablation in
F patients across all studies had been performed before
tudy initiation, and indication for ablation was not speci-
ed. Global biventricular capture rates for AF patients after
RT were reported in 2 studies: 75% in Gasparini et al. (21)
nd 82% in Molhoek et al. (20). These 2 investigators also
eported results of subsets of their patients who underwent
VJ ablation. Results reported here, however, represent all
F patients, inclusive of both AVJ ablated and nonablated
atients. Delnoy et al. (22) did not report global biventricu-
ar capture rates, but did observe that 90% of patients in AF
chieved a biventricular pacing percentage of 90%, 6%
chieved 50% to 90% biventricular pacing, and 4% were
iventricularly paced 50% despite medication adjust-
ents, thus necessitating AVJ ablation.
ll-cause mortality. A total of 85 deaths were reported
cross the included studies at 1 year (41 among AF patients
lysisa-Anand 44 in sinus rhythm patients). Although there was
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Cardiac Resynchronization in AF October 7, 2008:1239–46ncreased mortality in patients with AF, the calculation of
isk did not reach statistical significance (risk ratio: 1.57,
5% CI: 0.87 to 2.81, p  0.13) (Fig. 2). There was no
ignificant heterogeneity between studies (I2  47.5%).
mong 4 studies that reported cause of death, approxi-
ately 79% (weighted average) were from cardiovascular
auses, including stroke (18–20,22).
jection fraction. The LVEF improved significantly
cross all studies for both patients in sinus rhythm and
atients in AF. Average LVEF increased from 25.3% to
5.2% in patients with AF and from 24.6% to 33.8% for
hose in sinus rhythm. Although patients in AF had slightly
igher LVEF at baseline, they also showed a slightly greater
hange in LVEF (0.39% greater change in LVEF vs. those
n sinus rhythm, 95% CI: 0.22 to 0.55, p 0.0001) (Fig. 3).
here was a significant degree of heterogeneity for this
utcome (I2  97.1%). Notably, the method of calculating
VEF was not reported in standard fashion and could not
e compared between studies.
se of AVJ Ablation in AF Patients
Table 2 Use of AVJ Ablation in AF Patients
Study
AF Patients
Total AF
Patients
No. of Received
AVJ Ablation
% Received
AVJ Ablation
Delnoy et al. (22), 2007 96 21 22%
Gasparini et al. (21), 2006 162 114 70%
Molhoek et al. (20), 2004 30 17 57%
Linde et al. (18), 2002 64 40 63%
Leclercq et al. (19), 2000 15 15 100%
aseline Characteristics of Patients Included in Meta-Analysis
Table 1 Baseline Characteristics of Patients Included in Meta-
Delnoy et al. (22)
2007
Gasparini et al. (21)
2006
SR AF SR AF
Number of
patients
167 96 511 162
Age, mean  SD
(yrs)
729 738 63.410 668.3
Male gender (%) 68.3 75 77.3 85.8
Ischemic HF (%) NA NA 47.2 37.1
QRS duration,
mean (ms)
171 171 165.3 165
LVEDD, mean
(mm)
NA NA 67 66
Peak VO2, mean SD
(ml/min/kg)
NA NA 13.12.8 12.12.2
EF, mean (%) 22 25 26 26.3
6MWD, mean  SD
(m)
238124 262129 332117 311107
MLWHF score,
mean  SD
3517 3215 NA NA
NYHA functional
class III to IV (%)
78.8 76.9 89.7 96.9
Trial did not report separate percent male proportions for SR versus AF patients.
6MWD  6-min walking distance; AF  atrial fibrillation; EF  ejection fraction; HF  heart f
uestionnaire score; NA  not available; NYHA  New York Heart Association; Peak VO2  peakpVJ  atrioventricular junction; other abbreviations as in Table 1.hange in NYHA functional class. Four studies reported
ata on NYHA functional class (18–20,22). At baseline,
atients in AF had slightly more severe NYHA functional
lass heart failure than those in sinus rhythm (3.0 vs. 2.9,
 0.03). Overall, both groups improved by approximately
functional class, although patients in AF showed slightly
ess improvement on average (0.84 average change, 95%
I: 0.96 to 0.73 for AF patients; 0.90, 95% CI: 1.0
o0.8 for sinus rhythm patients; weighted mean difference
f change in NYHA functional class was 0.06, 95% CI: 0.04
o 0.08, p  0.0001) (Fig. 4).
unctional outcomes. Three studies reported the impact
f CRT on 6-min walking distance (6MWD) and the
LWHF questionnaire (18,20,22). Both AF and sinus
hythm patients showed significant improvements in
MWD; however, patients in sinus rhythm achieved a
reater relative improvement in 6MWD than their coun-
erparts in AF, walking 11.6 m further on average (95% CI:
0.4 to 12.8 m, p  0.0001) (Fig. 5A). Quality of life
mprovement, as measured by the MLWHF question-
aire, also favored patients in sinus rhythm (where lower
cores indicate an improved self-perceived QOL). At
aseline, QOL scores were similar across both groups
2.33 points higher for patients in sinus rhythm, p 
.17). Although both groups showed improvements in
LWHF scores (13.2 points lower for sinus rhythm
atients and 9.7 points lower for AF patients), patients in
inus rhythm achieved greater relative improvement (3.94
oints weighted mean difference, 95% CI: 3.35 to 4.54
sis
Molhoek et al. (20)
2004
Linde et al. (18)
2002 (MUSTIC)
Leclercq et al. (19)
2000
SR AF SR AF SR AF
30 30 67 64 22 15
88 6310 6310 659 678 686
80 90 75 81 91.9*
NA NA 37 27 45.5 26.7
NA NA 176 206 178 186
74 76 73 68 NA NA
NA NA 13.63.8 12.73.9 13.44.3 11.23.2
23 20 22 26 22 24
297 227113 32097 32880 NA NA
313 4317 4723 4523 NA NA
100 100 100 100 100 100
LVEDD  left-ventricular end-diastolic diameter; MLWHF  Minnesota Living with Heart Failure
m-limited oxygen consumption; SR  sinus rhythm.Analy
6
26
4oints, p  0.0001) (Fig. 5B).
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n this meta-analysis of prospective studies comparing CRT
n patients with AF and sinus rhythm, we find that patients
ith AF have similar or slightly greater improvements in
VEF than patients in sinus rhythm but have smaller
unctional benefits as measured by NYHA functional class,
MWD, and the MLWHF score. There were no signifi-
ant mortality differences from CRT in patients in AF and
inus rhythm at 1 year, although the CIs around this
stimate were wide, and thus we cannot exclude small
ortality differences between patients with AF and sinus
hythm.
Our analysis was limited in that of the 5 eligible studies
ielded from our literature search, 4 were prospective
bservational cohort studies. Particularly in light of an aging
atient population in whom the rate of AF is increasing
nnually, the need for a randomized controlled trial assess-
ng the impact of CRT in this important subgroup is clear.
hese limitations notwithstanding, the results across the
elected studies uniformly suggest that AF patients may
enefit from CRT. Patients with AF had improvements in
jection fraction (weighted mean improvement 8.6%, 95%
I: 7.1% to 10.1%, p  0.0001) (18–22), NYHA func-
Figure 2 All-Cause Mortality for Patients in SR Versus AF
AF  atrial fibrillation; CI  confidence interval; RR  relative risk; SR  sinus rhy
Figure 3 WMD in Change of Ejection Fraction for Patients in S
WMD  weighted mean difference; other abbreviations as in Figure 2.ional class (weighted mean improvement of 0.8, 95% CI:
.7 to 1.0, p  0.0001) (18–20,22), 6MWD (11.6 m 
aseline, 95% CI: 13.51 to 19.59 m, p  0.005) (18,20,22),
nd a better self-perceived QOL (MLWHF reduction of
.4 points, 95% CI: 13.38 to 5.37 points, p  0.0001)
18,20,22).
Frequently comorbid with heart failure, the prevalence of
F increases with severity of heart failure, affecting 5% to
0% of patients in NYHA functional classes I to II and as
igh as 50% of NYHA class IV patients (23,24). Although
ome data suggest that CRT might reduce the incidence of
F (25,26), recent data from large trials indicate that AF
ccurs similarly in CRT-treated patients versus those
ontrolled with pharmacotherapy alone, at a rate of 16%
er year (27,28). Indeed, even in CRT trials requiring
ormal sinus rhythm for enrollment, paroxysmal AF had
een present in up to 20% of patients in the year before
ntry (28). Our results suggest, however, that CRT may
till be associated with continued improvement in these
atients.
Echocardiographic improvement, in particular, seems
imilar for patients in AF versus those in sinus rhythm,
hereas functional benefits seem to lag. Potential con-
sus AFthm.R Ver
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Cardiac Resynchronization in AF October 7, 2008:1239–46ounders that may explain the differential performance
etween AF and sinus rhythm patients include the calcula-
ion of LVEF (which was not described in standard fashion
cross studies), heterogeneity in lead placement across both
atients and studies, and age of selected patients (which was
.6 years greater for AF patients). Prior investigations in
niventricular pacing devices postulated that tachycardia-
nduced cardiomyopathy may also drive poor outcomes for
F patients (29,30). This last rationale seems unlikely in the
selected studies for this analysis, because ventricular rates
or AF patients were kept in a narrow range (usually 70 to
0 beats/min). It is notable, however, that to maximally
eliver CRT, AF patients are often programmed to a higher
entricular rate than their counterparts in sinus rhythm.
Figure 4 WMD in Change of NYHA Functional Class for Patient
NYHA  New York Heart Association; other abbreviations as in Figures 2 and 3.
Figure 5 WMD in Change of 6MWD and Change of MLWH Scor
(A) Weighted mean difference (WMD) in change of 6-min walk distance (6MWD) fo
(B) Weighted mean difference in change of Minnesota Living With Heart Failure (Mhey may therefore see detriment from greater diastolic
ysfunction rather than rapid ventricular response.
Perhaps more important than rate control, insufficient
iventricular capture has been suggested by some investiga-
ors as the primary barrier to achieving optimal clinical
esponse after CRT for patients in AF. Erratic native
ctivity and electrical penetrance of the AV node may
verride the CRT device and interrupt ventricular syn-
hrony, particularly in situations of increased myocardial
emand (e.g., during stress or exercise). Gasparini et al. (21)
lso report that the occurrence of fusion or pseudofusion
eats between intrinsic conducted and paced beats tends to
verestimate percentage of biventricular stimulation time,
nd thus the true effective time of CRT delivery. In our
R Versus AF
Patients in SR Versus AF
nts in SR versus AF.
score for patients in SR versus AF. Abbreviations as in Figure 2.s in Se for
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October 7, 2008:1239–46 Cardiac Resynchronization in AFtudy, only limited data from Gasparini et al. (21) and
olhoek et al. (20) were available to confirm this hypoth-
sis, who reported that reduced mean global biventricular
apture rates (75% and 82%, respectively) were present in
F patients treated with CRT.
Gasparini et al. (21) and Molhoek et al. (20) also reported
eparately on the cohorts of their AF patients who were
reated with AVJ ablation. The AVJ-ablated patients
howed better response from CRT than their counterparts
n AF who were not ablated, as measured by LVEF and
YHA functional class. Gasparini et al. (21) and Molhoek
t al. (20) suggest, therefore, that AF patients who are CRT
esponders are only those who have undergone AVJ abla-
ion. Delnoy et al. (22), on the other hand, observed
ignificant benefit in their AF cohort despite a lower use of
VJ ablation. This may have been driven by higher rates of
iventricular capture in their study, in which 90% of AF
atients achieved 90% biventricular capture. Delnoy et al.
22) suggest that higher rates of amiodarone prescription,
hich doubled from 12% to 23% for AF patients treated
ith CRT, may have allowed for this response. Notably,
owever, the final rate of amiodarone prescription in the
tudy by Delnoy et al. (22) was comparable, but not
ignificantly higher, than in other studies that reported on
hese data. In Molhoek et al. (20) and Linde et al. (18),
verall amiodarone use also occurred in approximately
ne-quarter of patients before CRT.
Although it is uncertain whether AVJ ablation is required
or AF patients to yield benefit from CRT, concern regard-
ng its long-term safety has limited its general use. AVJ
blation has not been associated with an increase in mor-
ality based on current nonrandomized investigations (31),
hough there is a theoretical risk of device failure and death
n pacemaker-dependent patients. In an unpublished cohort
tudy by Gasparini et al. (32) following up 243 patients with
F treated with CRT, however, patients treated with AVJ
blation showed improved survival (4.3% mortality in AVJ-
blated patients vs. 15.2% for patients receiving medical
anagement). Given these data, it seems reasonable to
onsider AVJ ablation in patients with AF, although the
xtent of benefit and long-term safety of this approach still
emains to be determined.
Taken together, current guidelines regarding the use of
RT in patients with AF have been cautious, suggesting
hat there is a lack of evidence to support the use of CRT in
atients with AF, except for those with univentricular
evices that are being upgraded after AVJ ablation (33,34).
e find that even with variable use of AVJ ablation,
owever, CRT may be associated with clinical benefit for
atients in AF, and its use in these patients warrants
econsideration and further investigation with randomized
ontrolled trials.
tudy limitations. Our study has several potential limita-
ions. Although meta-analysis was first developed with
pplication to randomized controlled trials, this analytical
ethod is increasingly being applied to observational stud-es, including both cohort and case-control studies, because
f its strengths of transparency and reproducibility of
nalysis. This approach has enabled the rapid synthesis of
merging evidence and yield results that are hypothesis-
enerating, thereby hastening the call for further random-
zed trials.
Additionally, we restricted our selection criteria to pub-
ished studies, and therefore, may have been influenced by
ublication bias. Because we primarily explored the relative
erformance of CRT in patients with sinus rhythm versus
hose in AF, however, the extent of this bias should be
imilar for both groups, allowing for the analysis of differ-
nce that we have used. There was a significant degree of
eterogeneity among some outcomes (e.g., LVEF), and the
mall number of studies restricted our ability to perform
eta-regression and subgroup analysis. A more significant
imitation to our analysis is that our selected studies repre-
ent small prospective observational studies and, at baseline,
atients with AF show greater morbidity than patients in
inus rhythm. This may have mitigated the impact of CRT
n AF patients in these cohorts, and it would be worthwhile
o investigate the effect of CRT independently in patients
ith AF versus optimal medical management. Although our
nalysis is suggestive of benefit, the need for randomized
ontrol trials is clear. Finally, lack of uniformity in the
eporting of data regarding final lead position, and the use of
V optimization (for sinus rhythm patients), prevented us
rom substratifying the impact of these variables on outcomes.
onclusions
atients in AF treated by CRT benefit substantially and
ignificantly from CRT, although relative to patients in
inus rhythm, these benefits are greater in regard to echo-
ardiographic improvement and smaller in regard to func-
ional outcomes. There was no statistically significant dif-
erence in mortality between the 2 groups at 1 year,
lthough the CI around this estimate is broad and we
annot exclude clinically meaningful differences.
eprint requests and correspondence: Dr. Jagmeet P. Singh,
ardiac Arrhythmia Service, Cardiology Division, Gray Building
09, 55 Fruit Street, Boston, Massachusetts 02114. E-mail:
singh@partners.org.
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